• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

By: Apellis Pharmaceuticals, Inc. via GlobeNewswire
August 29, 2024 at 07:00 AM EDT

WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq: APLS) today announced that the company will participate in the following September investor conferences:

  • Wells Fargo Annual Healthcare Conference 2024: Fireside chat on Thursday, September 5, 2024, at 9:30 a.m. ET
  • Baird 2024 Global Healthcare Conference: Fireside chat on Wednesday, September 11, 2024, at 9:05 a.m. ET

The live conference webcasts will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcasts will be available for approximately 90 days following the event.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.

Investor Contact: 
Meredith Kaya 
meredith.kaya@apellis.com 
617.599.8178


Primary Logo

More News

View More
Palantir’s New Healthcare Deal Boosts AI and Data Reach
October 15, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers ONMD PLTR
GM's Billion-Dollar Bruise: GM's Strategic Pivot Makes It a Buy
October 15, 2025
Via MarketBeat
Topics Electric Vehicles
Tickers GM
Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s Lead
October 15, 2025
Via MarketBeat
Topics World Trade
Tickers LLY NVO SEPN
ASML Can Hit New Highs, But It Won’t Be Easy: Here’s Why
October 15, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers ASML
Vertiv Stock Surges on Strategic CFO Hire and AI Momentum
October 15, 2025
Via MarketBeat
Topics Artificial Intelligence
Tickers NVDA VRT WAB
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap